Development and validation of a method for the determination of the specific activity of recombinant monoclonal antibody eculizumab
Objectives. Developing reliable and accurate analytical methods is necessary for comparative pharmaceutical analysis using physicochemical, biological (in vitro), preclinical, and clinical trials. The main objective of this study was to develop and validate an in vitro method for determining the spe...
Saved in:
| Main Authors: | D. I. Zybin, A. S. Seregin, A. D. Askretkov, N. V. Orlova, Yu. A. Seregin, A. I. Prostyakova, D. V. Kapustin |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
MIREA - Russian Technological University
2020-05-01
|
| Series: | Тонкие химические технологии |
| Subjects: | |
| Online Access: | https://www.finechem-mirea.ru/jour/article/view/1599 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of iptacopan monotherapy for suboptimal response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria
by: Olesya U. Klimova, et al.
Published: (2025-01-01) -
A 2-decade survival from a double hemolytic disease: A case of paroxysmal nocturnal hemoglobinuria with hemoglobinopathy
by: Aria Namiq Chaqmachi, et al.
Published: (2024-12-01) -
The Advancing Landscape of Paroxysmal Nocturnal Hemoglobinuria Treatment
by: Cameron Perry, et al.
Published: (2025-06-01) -
Meningococcal Sepsis in Patient with Paroxysmal Nocturnal Hemoglobinuria during Pegcetacoplan Therapy
by: Leo Starck, et al.
Published: (2025-03-01) -
Striving for excellence in paroxysmal nocturnal hemoglobinuria in Canada: the EPIC program
by: Hayeong Rho, et al.
Published: (2025-07-01)